Fulvestrant

USDailyMed:Fulvestrant AU:D L02BA03(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol 129453-61-8Y 104741 1015 DB00947N 94553N 22X328QOC4 D01161N CHEBI:31638N ChEMBL1358N DTXSID4022369 Interactive image C[C@]12CC[C@@H]3c4ccc(O)cc4CC(CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O InChI=1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1Key:VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant, sold under the brand nameFaslodexamong others, is anantiestrogenicmedicationused to treat hormone receptor (HR)-positive metastaticbreast cancerinpostmenopausalwomen with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination withabemacicliborpalbociclibin women with disease progression after endocrine therapy.It is given byinjection into a muscle. Fulvestrant is aselective estrogen receptor degrader(SERD) and was first-in-class to be approved.It works by binding to theestrogen receptorand destabilizing it, causing the cell's normalprotein degradationprocesses to destroy it. Fulvestrant was approved for medical use in the United States in 2002.